Nektar Therapeutics (NKTR) Q2 2026 Earnings Call: REZPEG Phase III Advances
Source Tradingkey
Key Takeaways
- Nektar Therapeutics ended Q2 2026 with $1.02 billion in cash and investments and no debt. Management said the cash runway extends into Q3 2028, beyond the initial Phase III atopic dermatitis readouts expected in mid-2028.
- Q2 noncash royalty revenue was $10.1 million. Net loss totaled $40.6 million, or $1.23 per basic and diluted share.
- The global ZENITH-AD Phase III program for rezpegaldesleukin, or REZPEG, began randomizing patients in July. The first two studies target biologic- and JAK inhibitor-naive patients, while a treatment-experienced study is scheduled to begin by the end of September 2026.
- Following discussions with the FDA, Nektar finalized a single 850-patient registrational Phase III study for REZPEG in alopecia areata. The company plans to start ZENITH-AA in early 2027 and expects data in the second half of 2029.
- Nektar raised its year-end 2026 cash and investments guidance to $815 million-$840 million. Full-year revenue guidance remains $40 million-$45 million.
- Upcoming clinical catalysts include REZOLVE-AA off-treatment data in Q4 2026, atopic dermatitis off-treatment data in Q1 2027 and initial data from the TrialNet-sponsored type 1 diabetes study in 2027.
Core Financial Data
| Metric | Q2 2026 / Period End | Guidance or Context |
|---|---|---|
| Cash and investments | $1.02 billion | No debt; expected runway into Q3 2028 |
| Public offering proceeds | Approximately $350 million | Net proceeds from April 2026 offering |
| Noncash royalty revenue | $10.1 million | 2026 revenue guidance remains $40 million-$45 million |
| R&D expense | $39.1 million | 2026 guidance of $210 million-$230 million |
| G&A expense | $12.8 million | 2026 guidance of $60 million-$65 million |
| Noncash interest expense | $7.2 million | 2026 guidance of approximately $30 million-$35 million |
| Net loss | $40.6 million | $1.23 per basic and diluted share |
| Year-end cash and investments | — | Raised to $815 million-$840 million |
Business and Operating Performance
REZPEG Phase III program in atopic dermatitis
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Oil prices surged 5% following direct Israel-Iran strikes, while gold tumbled below $4,300 as a blowout U.S. jobs report fueled intense market anxieties over a December Federal Reserve rate hike.
XRP (XRP) price trades near $1.05, caught between a year-long downtrend and a sudden burst of buying.July has historically rewarded XRP holders. This year the month arrives with on-chain accumulation
Intel Corporation (NASDAQ: INTC) sits at $140.05, holding firm on the ascending trendline within the 2H timeframe. The RSI indicator is currently reading 55.21, positioning it as neutral-
Gold holds above $4,350 following weak US jobs data. As inflation reports approach and UBS eyes $5,000, can XAUUSD break resistance at $4,435 to rally toward $4,500?
Gold Price Analysis Today: Gold Drops 1.32% Despite Lower Fed Rate-Hike Bets, Can $4,313 Support Hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
